vaccine

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Shares of Pfizer Inc. traded today at $51.76, eclipsing its 52-week high. This new high was reached on approximately average trading...

Moderna Inc (NASDAQ: MRNA) shares are reversing course and are higher Tuesday. UK Expands Authorization: The UK drug regulator — the Medicines and Healthcare Products Regulatory Agency — announced Tuesday it has expanded the authorization given to Moderna's...

Novavax, Inc. (NASDAQ: NVAX) announced new hires to its executive team even as it is stymied by the delay in getting authorization for its COVID-19 vaccine in the U.S. What Happened: Novavax announced Monday it has appointed biopharma industry veteran Jim Kelly as executive vice president, CFO and...

Moderna Inc (NASDAQ: MRNA) announced a double dose of positive tidings Monday, but the stock is still wallowing in the red amid a sell-off seen across vaccine stocks. Moderna Augments Supply Deal With Canada: Cambridge, Massachusetts-based Moderna announced a revised supply agreement...

Inovio Pharmaceuticals Inc. (NASDAQ: INO) shares are trading higher Thursday alongside other vaccine maker stocks. Stocks have been trading higher recently as the COVIS-19 delta variant has been spreading throughout the U.S. Inovio Pharmaceuticals was up 13.45% at $9.70 at last check...

The sell-off in Moderna, Inc. (NASDAQ: MRNA)'s shares intensified Wednesday amid fears concerning stretched valuation and potential side effects from its mRNA vaccine. Moderna shares closed at a record high of $484.47 on Monday, propelled by optimism concerning its vaccine against the novel...

Moderna, Inc. (NASDAQ: MRNA) shares have rallied since the start of July, rendering the valuation unattractive and "ridiculous," according to a BofA Securities analyst.  The Moderna Analyst: Geoff Meacham maintained an Underperform rating on Moderna with a $115 price target....

State Of Fear Intensifies Over the weekend (Corona Doom 2.0), we mentioned Michael Crichton's observation about fear being used to facilitate social control, and we predicted governments would use threats of lockdowns to drive increased vaccination rates. We also wrote that one of our...

Ocugen Inc. (NASDAQ: OCGN) shares were trading higher Thursday in sympathy with other coronavirus vaccine stocks.  Vaccine stocks are likely moving after Moderna Inc. (NASDAQ: MRNA) reported the vaccine saw 93% efficacy six months after the second dose.  Ocugen was up 10.31% at $7.49 at...

Moderna Inc (NASDAQ: MRNA) shares traded higher Thursday after the company reported better-than-expected earnings per share and sales results. The company reported earnings per share of $6.46, beating the $6.04 estimate. Sales results came in at $4.4 billion, beating the estimate of $4.28...

Moderna, Inc. (NASDAQ: MRNA) and BioNTech SE (NASDAQ: BNTX) shares have been on tear ever since these companies embarked on their respective COVID-19 vaccine programs. Shares of both companies are trading just shy of their all-time highs. How Moderna, BioNTech Compare On COVID-19: Moderna, which...

Moderna, Inc. (NASDAQ: MRNA) shares have been on a stellar run in recent sessions amid COVID-19 induced momentum. he stock picked up further momentum after Standard & Poor's announced the inclusion of the vaccine maker in the S&P 500 Index. Pandemic Translates To Opportunity For...

Moderna, Inc. (NASDAQ: MRNA) shares appear to be going from strength to strength, and the premarket price action Tuesday suggests a positive open for the fifth straight session. What Happened: Cambridge, Massachusetts-based Moderna said Japan's Ministry of Health, Labor and Welfare and...

Novavax, Inc. (NASDAQ: NVAX) shares rallied higher Monday after renewed COVID-19 concerns. The new Delta variant has been spreading and is a major concern with it recently becoming the dominant strain of COVID-19. Retail traders have been pushing the stock up as concerns have...

For the second time in five weeks, the FDA has approved a new pneumococcal conjugate vaccine, this time giving the nod to a shot from Merck & Co Inc (NYSE: MRK). The vaccine, Vaxneuvance, is designed to protect against 15 strains of pneumococcal bacteria. That’s two more...